Pharming Group
- Country
- 🇳🇱Netherlands
- Ownership
- -
- Established
- 1988-11-11
- Employees
- 382
- Market Cap
- -
- Website
- www.pharming.com
- Introduction
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST?, Joenja?, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
Pharming Group to Acquire Abliva in $66.1 Million Deal, Bolstering Mitochondrial Disease Pipeline
Pharming Group N.V. has announced a public cash offer to acquire Abliva AB for approximately US$66.1 million, strengthening its pipeline.
Pharming's Leniolisib Shows Positive Phase 3 Data in Young Children with APDS
Pharming's leniolisib demonstrated positive topline results in a Phase 3 trial for children aged 4-11 with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS).
MHRA Approves Joenja (leniolisib) as First Treatment for Rare Immune Disease APDS
The MHRA has approved Joenja (leniolisib) as the first medicine for Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) in the UK.